Bristol mail room mishap permitted Geneva generic captopril approval -- BMS testimony.
Executive Summary
BRISTOL MAIL ROOM ERROR ALLOWED GENEVA CAPTOPRIL APPROVAL, Bristol outside counsel Robert Baechtold of the New York City firm Fitzpatrick, Cella, Harper & Scinto indicated during a Nov. 11 hearing before Newark, N.J. federal court Judge John Lifland. "Because Geneva's certification was never delivered to anybody at Bristol who was responsible for captopril, we didn't know about it, we didn't sue them. If we had sued them, they certainly would not be in the market today," he asserted.
You may also be interested in...
Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)
Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011